SARS-CoV-2 mRNA vaccines prevent severe COVID-19 by generating immune memory,
comprising specific antibodies and memory B and T cells. Although children are at low risk …

In this prospective observational cohort study we analyzed cellular and serological immune
response parameters against SARS-CoV-2 and current variants of concern (VOC) in 147 …

Background and objectives mRNA vaccines elicit a durable humoral response to SARS-CoV-
2 in adults, whereas evidence in children is scarce. This study aimed to assess the early and …

In light of the decreasing immune protection against symptomatic SARS-CoV-2 infection
after initial vaccinations and the now dominant immune-evasive Omicron variants,'booster' …

Although young children generally experience mild symptoms following infection with SARS-
CoV-2, severe acute and long-term complications can occur. SARS-CoV-2 mRNA vaccines …

This is the third year of the SARS-CoV-2 pandemic, and yet most children remain
unvaccinated. COVID-19 in children manifests as mostly mild or asymptomatic, however …

The efficacy of SARS-CoV-2 mRNA-based vaccines in preventing COVID-19 disease has
been extensively demonstrated; however, it is of uttermost importance to acquire knowledge …

Although the immunological memory produced by BNT162b2 vaccination against severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been well studied and …

Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is
effective in preventing hospitalization from severe COVID-19. However, multiple reports of …

At present, there is a lack of clinical evidence about the impact and long-term durability of
the immune response induced by the third dose of mRNA vaccines. In this study, we …